Behringwerke Aktiengesellschaft

Aventis Behring Gmbh

Csl Behring Gmbh

Zlb Behring Gmbh

Behringwerke Aktiengeseschaft

Gerhardt Kumpe

Norbert Heimburger

Horst Schwinn

Wilfried Wormsbacher

Hans M Preis

Stefan Schulte

Hubert Metzner

Hermann Erich Karges

Karlheinz Enssle

Peter Fuhge

Helmut Heber

Uwe Liebing

Thomas Nowak

Karl-Heinz Wenz

Klaus Wellner

Manfred Schick

Volker Gawantka

Bernd Herchenhan

Wilfried Wormsbaecher

Wilfried Wormsbächer

Heinz H Drescher

Wilfried Wormsb&auml;cher

Eckhard Schueler

Natascha Mayer

Manfred Juraschek

The invention relates to a concentrate and a process for producing a factor VIII:C-containing von Willebrand factor by fractional precipitation from a liquid comprising factor VIII:C and von Willebrand factor, resulting in an increased content of high molecular weight multimers of von Willebrand factor and a ratio of the vWF:RCoF activity to vWF:Ag of greater than 1.

Concentrate of a factor VIII:C-containing von Willebrand factor and the process relating thereto

The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form comprising divalent metal ions. The fibrinogen formulation may comprise other conventional formulation ingredients and particularly preferably comprises a complexing agent. The invention further relates to the production and use of the fibrinogen formulation of the invention.

Storage-stable, liquid fibrinogen formulation

A process for the inactivation and/or elimination of coated and/or noncoated viruses from a plasma protein solution by addition of an ammonium salt at alkaline pHs is described, in which a chromatographically prepurified plasma protein solution is subjected to an incubation at room temperature and at an ammonium salt concentration of 13 to 22% by weight, pasteurized at approximately 60&deg; C. for several hours after separation of the precipitates and removal of the ammonium salt down to a residual content of less than 0.5 mol/l and then processed to give a therapeutically employable plasma protein preparation.

Process for the inactivation of viruses

The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calcium ions and a chelating agent and, optionally, an amino acid, a saccharide or sugar alcohol, antithrombin III and/or heparin. The product can be used for the treatment of blood coagulation disorders.

Process for the pasteurization of plasma or concentrates of blood coagulation factors II, VII, IX and X

A process for the preparation of a pasteurized factor VIII concentrate with high specific activity and stability is described, which comprises adsorbing impurities from the solution containing the factor VIII by at least two-fold adsorption with Al(OH).sub.3, an anion exchanger or Ca.sub.3 (PO.sub.4).sub.2, preferably with two different adsorbents from this group.

Process for the preparation of a stable factor VIII

A process for the production of a preparation of blood coagulation factor VIII which makes it possible to obtain a pasteurized product which is virtually free of immunoglobulins, isoagglutinins, fibronectin and coagulable fibrinogen is described. A product of this type can be used for the treatment of blood coagulation disturbances.

Pasteurized, isoagglutinin-free factor VIII preparation and a process

A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Pasteurized human fibrinogen (HF), a process for its preparation, and

A process for the preparation of a pasteurized human citrated plasma is described, in which citrated plasma, from which the prothrombin factors and labile proteins have been removed, is heated in the presence of stabilizers.

Process for the pasteurization of human residual plasma

A process for the pasteurization of antihemophilic cryoprecipitate (AHC) is described, wherein AHC is heated in the presence of calicum ions, an amino acid and a carbohydrate. The pasteurized AHC is used for the treatment of coagulation disturbances.

Process for the pasteurization of antihemophilic cryoprecipitate (AHC)

What is disclosed is a process for rendering plasminogen virtually free of hepatitis virus by heating a plasminogen solution in the presence of a proteinase inhibitor with plasmin specificity, an amino acid, and a saccharide or sugar alcohol.

Process for the preparation of plasminogen and plasminogen thus prepared

A process for purifying liquids containing blood clotting factors by adsorption of the factors on mineral adsorbents such as calcium phosphate, aluminum hydroxide gel, barium sulfate or hydroxylapatite in the presence of calcium ions followed by elution is described.

Process for the purification of the blood clotting factors, II, VII, IX

What is disclosed is a method for making a preparation containing blood clotting Factors IX and/or X virtually hepatitis-safe by warming said peparation in the presence of calcium ions and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Method for rendering factors IX and X hepatitis-safe with calcium ions

What is disclosed is a method for treating a preparation containing blood clotting Factors II and/or VII to render it virtually hepatitis-free by warming said preparation in the presence of a chelating agent and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Method for rendering factors II and VII hepatitis-safe with a chelating

A process for stabilizing the coagulation factors II, VIII, XIII, antithrombin III and plasminogen against heat is described. The preparations obtained according to this process are practically free from coagulable fibrinogen.

Growing community of inventors

Wetter, Germany

Gerhardt Kumpe